Related references
Note: Only part of the references are listed.Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma
Jun Ho Ji et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)
Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA
Ghassan K. Abou-Alfa et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Pathological Complete Response to Lenvatinib after Failure of Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Yusuke Johira et al.
LIVER CANCER (2022)
Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference
Josep M. Llovet et al.
HEPATOLOGY (2021)
Predictive biomarkers for systemic therapy of hepatocellular carcinoma
Nurbubu T. Moldogazieva et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2021)
Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines
A. Vogel et al.
ANNALS OF ONCOLOGY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab
Shigeki Yano et al.
MEDICINE (2021)
Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes
Zowi R. Huinen et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma
Arndt Vogel et al.
LIVER CANCER (2021)
Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice
Yuwa Ando et al.
CANCERS (2021)
Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges
Shu-Jin Li et al.
CANCER COMMUNICATIONS (2021)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Tumor Fibroblast Growth Factor Receptor 4 Level Predicts the Efficacy of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma
Masami Yamauchi et al.
Clinical and Translational Gastroenterology (2020)
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
Masatoshi Kudo
LIVER CANCER (2020)
Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma A Systematic Review and Network Meta-analysis
Mohamad Bassam Sonbol et al.
JAMA ONCOLOGY (2020)
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline
John D. Gordan et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Comparing the efficacy and safety of second-line therapies for advanced hepatocellular carcinoma: a network meta-analysis of phase III trials
Dongxu Wang et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2020)
Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
Li-Chun Lu et al.
LIVER CANCER (2019)
Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies
James J. Harding et al.
CLINICAL CANCER RESEARCH (2019)
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2019)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
G. K. Abou-Alfa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients
Akio Osa et al.
JCI INSIGHT (2018)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
Metastatic spread in patients with non-small cell lung cancer is associated with a reduced density of tumor-infiltrating T cells
Philipp Mueller et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Microvascular invasion in hepatocellular carcinoma
Emre Unal et al.
DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY (2016)
Roles of regulatory T cells in cancer immunity
Yoshiko Takeuchi et al.
INTERNATIONAL IMMUNOLOGY (2016)
Microvascular invasion in hepatocellular carcinoma
Emre Unal et al.
DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY (2016)
Classifying Cancers Based on T-cell Infiltration and PD-L1
Michele W. L. Teng et al.
CANCER RESEARCH (2015)
Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models
Osamu Tohyama et al.
JOURNAL OF THYROID RESEARCH (2014)
A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours
D. S. Boss et al.
BRITISH JOURNAL OF CANCER (2012)
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
Riccardo Lencioni et al.
SEMINARS IN LIVER DISEASE (2010)
Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: New aspects and applications
Evi N. Debruyne et al.
CLINICA CHIMICA ACTA (2008)
Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase
Junji Matsui et al.
CLINICAL CANCER RESEARCH (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition
Junji Matsui et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Share Paper
